Document:

Blueprint

 

 Exhibit 4.4

REGISTRATION RIGHTS AGREEMENT

This
Registration Rights Agreement (this “Agreement”) is made and entered
into effective as of April 8, 2016 (the “Effective Date”) between Adgero
Biopharmaceuticals Holdings, Inc., a Delaware corporation (the
“Company”), and
the persons who have executed the signature page(s) hereto (each, a
“Purchaser” and
collectively, the “Purchasers”).

RECITALS:

WHEREAS, the
Company has entered into an Agreement and Plan of Merger with
Adgero Biopharmaceuticals, Inc., a Delaware corporation
(“Adgero”),
pursuant to which Adgero
Acquisition, Inc., a newly organized, wholly-owned subsidiary of
the Company has merged with and into Adgero, with Adgero remaining
as the surviving entity and a wholly-owned subsidiary of the
Company (the “Merger”);

WHEREAS,
simultaneously with the Merger and to provide the capital required
by the Company for working capital and other purposes, the Company
has offered in compliance with Rule 506(b) of Regulation D of the
Securities Act (as defined herein), to accredited investors in a
private placement transaction (the “PPO”), units (“Units”) of its securities, each
consisting of: (i) one (1) share of Common Stock (as defined below)
(the “Investor
Shares”), and (ii) a five-year warrant (the
“Investor
Warrants”) to purchase one (1) share of Common Stock
at an initial exercise price of $5.00 per Share;

WHEREAS, the
initial closing of the PPO and the closing of the Merger have taken
place on the Effective Date;

WHEREAS, in
connection with the Merger, the holders of certain warrants to
purchase Adgero Common Stock were issued new warrants to purchase
30,864 shares of Company Common Stock (the “Replacement
Warrants”);

WHEREAS,
simultaneously with the Merger and the PPO, certain of the
Company’s 6% convertible notes held by certain investors (the
“Bridge
Holders”) in the aggregate principal amount of
$35,000 (the
“Bridge Notes”),
will automatically convert into a quantity of Units equal to the
principal amount of Bridge Notes held by such Bridge Holders,
together with accrued interest thereon calculated through the date
of the initial closing of the PPO, divided by $5.00 (the
“Conversion”);
and

WHEREAS, in
connection with the Merger and the PPO, the Company agreed to
provide certain registration rights related to the Investor Shares
and the shares of Common Stock issuable upon exercise of the
Investor Warrants and Replacement Warrants, on the terms set forth
herein.

NOW,
THEREFORE, in consideration of the mutual promises,
representations, warranties, covenants, and conditions set forth
herein, the parties mutually agree as follows:

1. Certain Definitions. As used in
this Agreement, the following terms shall have the following
respective meanings:

 

1

 

“Agreement” has the
meaning given it in the preamble to this Agreement.

“Allowed Delay” has the
meaning given it in Section 3(e) of this Agreement.

“Approved Market” means
the Over-the-Counter Bulletin Board, the OTC Markets, the Nasdaq
Stock Market, the New York Stock Exchange or the NYSE
MKT.

“Blackout Period” means,
with respect to a registration, a period, in each case commencing
on the day immediately after the Company notifies the Purchasers
that they are required, because of the occurrence of an event of
the kind described in Section 4(f) hereof, to suspend offers and
sales of Registrable Securities during which the Company, in the
good faith judgment of its board of directors, determines (because
of the existence of, or in anticipation of, any acquisition,
financing activity, or other transaction involving the Company, or
the unavailability for reasons beyond the Company’s control
of any required financial statements, disclosure of information
which is in its best interest not to publicly disclose, or any
other event or condition of similar significance to the Company)
that the registration and distribution of the Registrable
Securities to be covered by such Registration Statement, if any,
would be seriously detrimental to the Company and its stockholders
and ending on the earlier of (1) the date upon which the material
non-public information commencing the Blackout Period is disclosed
to the public or ceases to be material and (2) such time as the
Company notifies the selling Holders that the Company will no
longer delay such filing of the Registration Statement, recommence
taking steps to make such Registration Statement effective, or
allow sales pursuant to such Registration Statement to
resume.

“Bridge Holders” has the
meaning given in the recitals of this Agreement.

“Bridge Notes” has the
meaning given in the recitals of this Agreement.

“Business Day” means any
day of the year, other than a Saturday, Sunday, or other day on
which the Commission is required or authorized to
close.

“Closing Price” has the
meaning given it in Section 3(f) of this Agreement.

“Commission” means the U.
S. Securities and Exchange Commission or any other applicable
federal agency at the time administering the Securities
Act.

“Common Stock” means the
common stock, par value $0.0001 per share, of the Company and any
and all shares of capital stock or other equity securities of: (i)
the Company which are added to or exchanged or substituted for the
Common Stock by reason of the declaration of any stock dividend or
stock split, the issuance of any distribution or the
reclassification, readjustment, recapitalization or other such
modification of the capital structure of the Company; and (ii) any
other corporation, now or hereafter organized under the laws of any
state or other governmental authority, with which the Company is
merged, which results from any consolidation or reorganization to
which the Company is a party, or to which is sold all or
substantially all of the shares or assets of the Company, if
immediately after such merger, consolidation, reorganization or
sale, the Company or the stockholders of the Company own equity
securities having in the aggregate more than 50% of the total
voting power of such other corporation.

 

2

 

“Company” has the meaning
given it in the preamble to this Agreement.

“Conversion” has the
meaning given in the recitals of this Agreement.

“Effective Date” has the
meaning given it in the preamble to this Agreement.

“Effectiveness Period” has
the meaning given it in Section 4(a) of this
Agreement.

“Exchange Act” means the
Securities Exchange Act of 1934, as amended, and the rules and
regulations of the Commission promulgated thereunder.

“Family Member” means (a)
with respect to any individual, such individual’s spouse, any
descendants (whether natural or adopted), any trust all of the
beneficial interests of which are owned by any of such individuals
or by any of such individuals together with any organization
described in Section 501(c)(3) of the Internal Revenue Code of
1986, as amended, the estate of any such individual, and any
corporation, association, partnership or limited liability company
all of the equity interests of which are owned by those above
described individuals, trusts or organizations and (b) with respect
to any trust, the owners of the beneficial interests of such
trust.

 “Holder”
means each Purchaser, including any Bridge Holder, or any of such
Purchaser’s or Bridge Holder’s respective successors
and Permitted Assignees who acquire rights in accordance with this
Agreement with respect to any Registrable Securities directly or
indirectly from a Purchaser or Bridge Holder or from any Permitted
Assignee.

“Initial Public Offering”
means the
initial underwritten sale of equity securities by the Company
pursuant to an effective Registration Statement under the
Securities Act.

 “IPO
Engagement” has the meaning given it in Section 3(a)
of this Agreement.

“IPO Process Commencement
Date” has the meaning given it in Section 3(a) of this
Agreement.

“Investor Shares” has the
meaning given it in the recitals of this Agreement.

“Investor Warrants” has
the meaning given it in the recitals of this
Agreement.

“Joint Registrations
Statement” has the meaning given it in Section 3(a) of
this Agreement.

“Majority Holders” means
at any time Holders representing a majority of the Registrable
Securities.

“Merger” has the meaning
given in the recitals of this Agreement.

 “Permitted
Assignee” means (a) with respect to a partnership, its
partners or former partners in accordance with their partnership
interests, (b) with respect to a corporation, its stockholders in
accordance with their interest in the corporation, (c) with respect
to a limited liability company, its members or former members in
accordance with their interest in the limited liability company,
(d) with respect to an individual party, any Family Member of such
party, (e) an entity that is controlled by, controls, or is under
common control with a transferor, or (f) a party to this
Agreement.

 

3

 

“Piggyback Registration”
means, in any registration of Common Stock as set forth in Section
3(b), the ability of holders of Registrable Securities to include
Registrable Securities in such registration.

“PPO” has the meaning
given in the recitals of this Agreement.

“Purchaser” has the
meaning given it in the preamble to this Agreement.

“Qualified Purchaser” has
the meaning given it in Section 3(d) of this
Agreement.

“Redemption Notice” has
the meaning given it in Section 3(f) of this
Agreement.

The
terms “register,”
“registered,” and
“registration” refer to a
registration effected by preparing and filing a registration
statement in compliance with the Securities Act, and the
declaration or ordering of the effectiveness of such registration
statement.

“Registrable Securities”
means the Investor Shares and the Registrable Warrant Shares but
excluding, subject to Section 3(e), (i) any Registrable Securities
that have been publicly sold or may be sold immediately without
registration under the Securities Act either pursuant to Rule 144
of the Securities Act or otherwise; (ii) any Registrable Securities
sold by a person in a transaction pursuant to a registration
statement filed under the Securities Act, or (iii) any Registrable
Securities that are at the time subject to an effective
registration statement under the Securities Act.

 “Registrable
Warrant Shares” means the shares of Common Stock
issued or issuable to each Holder upon exercise of the Investor
Warrants or Replacement Warrants, as the case may be.

“Registration Default
Date” means the date that is 150 days after the date
the Registration Statement is actually filed with the Commission;
provided however that the Registration Default Date is subject to
adjustment as set forth under Section 3(a) of this
Agreement

“Registration Default
Period” means the period following the Registration
Default Date during which any Registration Event occurs and is
continuing.

“Registration Event” means
the occurrence of any of the following events:

(a) the Company fails
to file with the Commission the Registration Statement on or before
the Registration Filing Date;

(b) the Registration
Statement is not declared effective by the Commission on or before
the Registration Default Date;

 

4

 

(c) after the SEC
Effective Date, sales cannot be made pursuant to the Registration
Statement for any reason (including without limitation by reason of
a stop order, or the Company’s failure to update the
Registration Statement) except as excused pursuant to Section 3(e);
or

(d) 20
days after the SEC Effective Date, the Common Stock generally or
the Registrable Securities specifically are not listed or included
for quotation on an Approved Market, or trading of the Common Stock
is suspended or halted on the Approved Market, which at the time
constitutes the principal market for the Common Stock, for more
than two full, consecutive Trading Days; provided, however, that
such 20 day delay in the Common Stock being listed on an Approved
Market shall only be granted in the event the delay is solely the
result of issues raised by the Approved Market subsequent to the
SEC Effective Date and provided that the Company uses its
commercially reasonable efforts in curing any issues resulting in
such delay.

provided, however, a Registration Event
shall not be deemed to occur if: (1) all or substantially all
trading in equity securities (including the Common Stock) is
suspended or halted on the Approved Market for any length of time;
(2) the Company commences and pursues an Initial Public Offering,
as set forth in Section 3(a) of this Agreement; or (3) the Company
declares a Blackout Period; provided however that the Company shall
only be permitted to declare two (2) Blackout Periods per
year.

“Registration Filing Date”
means the date that is 60 days after date of the final closing of
the PPO, or if later, the termination of the PPO following an
initial closing of the PPO; provided however, that the Registration
Filing Date is subject to adjustment as set forth under Section
3(a) of this Agreement.

“Registration Statement”
means the registration statement that the Company is required to
file pursuant to this Agreement to register the Registrable
Securities.

“Release Date” has the
meaning given it in Section 3(f) of this Agreement.

“Replacement Warrants” has
the meaning given in the recitals of this Agreement.

“Rule 144” means Rule 144
promulgated by the Commission under the Securities
Act.

“Rule 145” means Rule 145
promulgated by the Commission under the Securities
Act.

“Rule 415” means
Rule 415 promulgated by the Commission pursuant to the
Securities Act, as such Rule may be amended from time to time, or
any similar rule or regulation hereafter adopted by the SEC having
substantially the same purpose and effect as such
Rule.

“Rule 424” means
Rule 424 promulgated by the Commission pursuant to the
Securities Act, as such Rule may be amended from time to time, or
any similar rule or regulation hereafter adopted by the SEC having
substantially the same purpose and effect as such
Rule.

 

5

 

“Securities Act” means the
Securities Act of 1933, as amended, or any similar federal statute
promulgated in replacement thereof, and the rules and regulations
of the Commission thereunder, all as the same shall be in effect at
the time.

“SEC Effective Date” means
the date the Registration Statement is declared effective by the
Commission.

“Trading Day” means (a) if
the Common Stock is listed or quoted on an Approved Market, then
any day during which securities are generally eligible for trading
on the Approved Market, or (b) if the Common Stock is not then
listed or quoted and traded on an Approved Market, then any
Business Day.

“Transfer” has the meaning
given it in Section 3(f) of this Agreement.

“Units” has the meaning
given in the recitals of this Agreement.

2. Term. This Agreement shall
continue in full force and effect for a period of one year from the
SEC Effective Date, unless terminated sooner
hereunder.

3. Registration.

(a) Registration on Form S-1. Not
later than the Registration Filing Date, the Company shall file
with the Commission a Registration Statement on Form S-1, or other
applicable form, relating to the resale by the Holders of all of
the Registrable Securities, and the Company shall use its
commercially reasonably efforts to cause such Registration
Statement to be declared effective prior to the Registration
Default Date; provided, however, that in the event the
Company signs a letter of intent or comparable agreement with an
underwriter which contemplates an Initial Public Offering or holds
an organizational meeting for an Initial Public Offering or
otherwise orally engages an underwriter to begin working with the
Company towards an Initial Public Offering (an “IPO
Engagement”) prior
to the Registration Default Date (such applicable date, the
“IPO Process Commencement
Date”), then the Company shall, in satisfaction of the
foregoing obligation, file a joint registration statement covering
the primary shares to be issued in the Initial Public Offering and
the resale of  the Registrable Securities (”Joint Registration Statement”),
and, in such event, the  Registration Filing Date shall be
extended to a date that is seventy five (75) calendar days after
the IPO Process Commencement Date and the Registration Default Date
shall be extended to a date that is one hundred twenty (120)
calendar days after the initial filing of the Registration
Statement with the Commission.  If the Initial Public Offering
is abandoned at any time, then the Registration Filing Date will be
60 calendar days from the actual date of abandonment and the
Registration Default Date will be one hundred and fifty (150)
calendar days after the date of abandonment. The registration
rights under Section 3 shall not apply or be available to certain
affiliate holders.

(b) Piggyback Registration. In
addition to the Company agreement pursuant to Section 3(a) above,
if the Company shall determine to register for sale for cash any of
its Common Stock, for its own account or for the account of others
(other than the Holders), other than (i) Initial Public Offering,
(ii) a registration relating solely to employee benefit plans or
securities issued or issuable to employees, consultants (to the
extent the securities owned or to be owned by such consultants
could be registered on Form S-8) or any of their Family Members
(including a registration on Form S-8) or (iii) a registration
relating solely to a Securities Act Rule 145 transaction or a
registration on Form S-4 in connection with a merger, acquisition,
divestiture, reorganization or similar event, the Company shall
promptly give to the Holders written notice thereof (and in no
event shall such notice be given less than 20 calendar days prior
to the filing of such registration statement), and shall, subject
to Section 3(c), include as a Piggyback Registration all of the
Registrable Securities specified in a written request delivered by
the Holder thereof within 10 calendar days after receipt of such
written notice from the Company. However, the Company may, without
the consent of the Holders, withdraw such registration statement
prior to its becoming effective if the Company or such other
stockholders have elected to abandon the proposal to register the
securities proposed to be registered thereby.

 

6

 

(c) Underwriting. If a Piggyback
Registration is for a registered public offering that is to be made
by an underwriting, the Company shall so advise the Holders of the
Registrable Securities eligible for inclusion in such Registration
Statement pursuant to Sections 3(b). In that event, the right of
any Holder to Piggyback Registration shall be conditioned upon such
Holder’s participation in such underwriting and the inclusion
of such Holder’s Registrable Securities in the underwriting
to the extent provided herein. All Holders proposing to sell any of
their Registrable Securities through such underwriting shall
(together with the Company and any other stockholders of the
Company selling their securities through such underwriting) enter
into an underwriting agreement in customary form with the
underwriter selected for such underwriting by the Company or the
selling stockholders, as applicable. Notwithstanding any other
provision of this Section, if the underwriter or the Company
determines that marketing factors require a limitation on the
number of shares of Common Stock or the amount of other securities
to be underwritten, the underwriter, at its sole discretion, may
exclude some or all Registrable Securities from such registration
and underwriting. The Company shall so advise all Holders (except
those Holders who failed to timely elect to include their
Registrable Securities through such underwriting or have indicated
to the Company their decision not to do so), and indicate to each
such Holder the number of shares of Registrable Securities that may
be included in the registration and underwriting, if any. The
number of shares of Registrable Securities to be included in such
registration and underwriting shall be allocated among such Holders
as follows:

(i) If the Piggyback
Registration was initiated by the Company, the number of shares
that may be included in the registration and underwriting shall be
allocated first to the Company and then, subject to obligations and
commitments existing as of the date hereof, to all selling
stockholders, including the Holders, who have requested to sell in
the registration on a pro rata basis according to the number of
shares requested to be included therein; or

(ii) If
the Piggyback Registration was initiated by the exercise of demand
registration rights by a stockholder or stockholders of the Company
(other than the Holders), then the number of shares that may be
included in the registration and underwriting shall be allocated
first to such selling stockholders who exercised such demand and
then, subject to obligations and commitments existing as of the
date hereof, to all other selling stockholders, including the
Holders, who have requested to sell in the registration on a pro
rata basis according to the number of shares requested to be
included therein.

 

7

 

No
Registrable Securities excluded from the underwriting by reason of
the underwriter’s marketing limitation shall be included in
such registration and no liquidated damages as set forth in Section
3(d) shall accrue with respect to such excluded securities. If any
Holder disapproves of the terms of any such underwriting, such
Holder may elect to withdraw such Holder’s Registrable
Securities therefrom by delivering a written notice to the Company
and the underwriter. The Registrable Securities so withdrawn from
such underwriting shall also be withdrawn from such registration;
provided,
however, that, if
by the withdrawal of such Registrable Securities, a greater number
of Registrable Securities held by other Holders may be included in
such registration (up to the maximum of any limitation imposed by
the underwriters), then the Company shall offer to all Holders who
have included Registrable Securities in the registration the right
to include additional Registrable Securities pursuant to the terms
and limitations set forth herein in the same proportion used above
in determining the underwriter limitation.

(d) Occurrence
of Registration Event. If a Registration Event occurs, then
the Company will make payments to each Holder of Registrable
Securities (a “Qualified
Purchaser”), as liquidated damages for the amount of
damages to the Qualified Purchaser by reason thereof, at a rate
equal to 0.50% of the purchase price per Unit paid by such Holder
in the PPO for the Registrable Securities then held by each
Qualified Purchaser for each full period of 30 days of the
Registration Default Period (which shall be pro-rated for any
period less than 30 days); provided, however, if a Registration
Event occurs (or is continuing), liquidated damages shall be paid
only with respect to that portion of the Qualified
Purchaser’s Registrable Securities that cannot then be
immediately resold in reliance on Rule 144. Notwithstanding the
foregoing, the maximum amount of liquidated damages that may be
paid to any Qualified Purchaser pursuant to this Section 3(d) shall
be an amount equal to 6% of the purchase price per Unit paid by
such Holder in the PPO for the Registrable Securities held by such
Qualified Purchaser at the time of the first occurrence of a
Registration Event. Each such payment shall be due and payable
within five days after the end of each full 30-day period of the
Registration Default Period until the termination of the
Registration Default Period and within five days after such
termination. Such payments shall constitute the Qualified
Purchaser’s exclusive remedy for such events. If the Company
fails to pay any partial liquidated damages or refund pursuant to
this Section in full within seven days after the date payable, the
Company will pay interest thereon at a rate of 2% per annum (or
such lesser maximum amount that is permitted to be paid by
applicable law) to the Holder, accruing daily from the date such
partial liquidated damages are due until such amounts, plus all
such interest thereon, are paid in full. The Registration Default
Period shall terminate upon (i) the filing of the Registration
Statement in the case of clause (a) of the definition of
Registration Event, (ii) the SEC Effective Date in the case of
clause (b) of the definition of Registration Event, (iii) the
ability of the Qualified Purchaser to effect sales pursuant to the
Registration Statement in the case of clause (c) of the definition
of Registration Event, and (iv) the listing or inclusion and/or
trading of the Common Stock on an Approved Market, as the case may
be, in the case of clause (d) of the definition of Registration
Event. The amounts payable as liquidated damages pursuant to this
Section 3(d) shall be payable in lawful money of the United
States.

(e) Notwithstanding the
provisions of Section 3(d) above:

 

8

 

(1)(a)
if the Commission does not declare the Registration Statement
effective on or before the Registration Default Date, or (b) if the
Commission allows the Registration Statement to be declared
effective at any time before or after the Registration Default
Date, subject to the withdrawal of certain Registrable Securities
from the Registration Statement, and the reason for (a) or (b) is
the Commission’s determination that (x) the offering of any
of the Registrable Securities constitutes a primary offering of
securities by the Company, (y) Rule 415 may not be relied upon for
the registration of the resale of any or all of the Registrable
Securities, and/or (z) a Holder of any Registrable Securities must
be named as an underwriter, the Holders understand and agree that
in the case of (b) the Company may reduce, on a pro rata basis, the total number of
Registrable Securities to be registered on behalf of each such
Holder, and, in the case of (a) or (b), that a Holder shall not be
entitled to any liquidated damages with respect to the Registrable
Securities not registered for the reason set forth in (a), or so
reduced on a pro rata basis
as set forth in (b). In any such pro rata reduction, the number of
Registrable Securities to be registered on such Registration
Statement will be reduced (i) first, by the Registrable Securities
represented by the Registrable Warrant Shares (applied, in the case
that some Registrable Warrant Shares may be registered, to the
Holders on a pro rata basis
based on the total number of unregistered Registrable Warrant
Shares held by such Holders on a fully diluted basis) and (ii)
second, by the Registrable Securities represented by Investor
Shares (applied, in the case that some Investor Shares may be
registered, to the Holders on a pro rata basis based on the total
number of unregistered Investor Shares held by such
Holders). In addition, any
such affected Holder shall be entitled to Piggyback Registration
rights after the Registration Statement is declared effective by
the Commission until such time as: (AA) all Registrable Securities
have been registered pursuant to an effective Registration
Statement, (BB) the Registrable Securities may be resold without
restriction pursuant to Rule 144 of the Securities Act, or (CC) the
Holder agrees to be named as an underwriter in any such
registration statement. The Holders acknowledge and agree the
provisions of this paragraph may apply to more than one
Registration Statement; and

(2)           For
not more than thirty (30) consecutive days or for a total of not
more than sixty (60) days in any twelve (12) month period, the
Company may suspend the use of any prospectus included in any
Registration Statement contemplated by this Section in the event
that the Company determines in good faith that such suspension is
necessary to (A) delay the disclosure of material non-public
information concerning the Company, the disclosure of which at the
time is not, in the good faith opinion of the Company, in the best
interests of the Company or (B) amend or supplement the affected
Registration Statement or the related prospectus so that such
Registration Statement or prospectus shall not include an untrue
statement of a material fact or omit to state a material fact
required to be stated therein or necessary to make the statements
therein, in the case of the prospectus in light of the
circumstances under which they were made, not misleading, including
in connection with the filing of a post-effective amendment to such
Registration Statement in connection with the Company’s
filing of an Annual Report on Form 10-K for any fiscal year (an
“Allowed
Delay”); provided, that the Company shall promptly (a)
notify each Holder in writing of the commencement of an Allowed
Delay, but shall not (without the prior written consent of an
Holder) disclose to such Holder any material non-public information
giving rise to an Allowed Delay, (b) advise the Holders in writing
to cease all sales under the Registration Statement until the end
of the Allowed Delay and (c) use commercially reasonable efforts to
terminate an Allowed Delay as promptly as practicable.

 

9

 

In the
event of an Allowed Delay, the liquidated damages set forth in
Section 3(d) shall not accrue during such Allowed
Delay.

(f)           Holdback
Agreements. (A) Subject to paragraphs (B) and (C) below,
from and after the SEC Effective Date, each Holder understands that
(i) it shall not sell, offer, pledge, contract to sell, grant any
option or contract to purchase, purchase any option or contract to
sell, grant any right or warrant to purchase, lend or otherwise
transfer or encumber, directly or indirectly, any shares of the
Registrable Securities, nor shall such Holder enter into any swap,
hedging or other arrangement that transfers to another, in whole or
in part, any of the economic consequences of ownership of any
shares of the Registrable Securities (any of the foregoing under
(i), a “Transfer”) until the Release Date
(as defined below); provided, however, that such Holder shall
be permitted to Transfer up to 25% of such Holder’s Investor
Shares held by it, as the case may be, at any time on or after the
SEC Effective Date, and (ii) following the SEC Effective Date, it
shall be entitled to Transfer up to an additional 25% of such
Holder’s Investor Shares beginning at the end of each
successive 90 day period thereafter, such that after the Release
Date, all Registrable Securities (i.e. Investor Shares and
Registrable Warrant Shares) held by such Holder may be Transferred.
Each Holder hereby covenants and agrees that (x) it shall abide by
the restrictions set forth above and (y) the Company shall be
entitled to place “stop transfer” instructions with the
Company’s transfer agent in compliance with the above
restrictions. For purposes of this clause (f), the term
“Release Date”
shall mean 270 days from the SEC Effective Date; provided, that in
the event the Company delivers a notice of redemption to the
Holders of the Investor Warrants or the Replacement Warrants
(pursuant to the terms of such warrants) (the “Redemption Notice”), the
restrictions set forth above shall terminate effective on the date
of delivery of the Redemption Notice.

 

(B)
Notwithstanding Section 3(f)(A) above, in the event the Closing
Price is $15.00 or above (as adjusted for any stock split, share
dividends, share combinations, or the like) for 20 consecutive
Trading Days, all Registrable Securities shall be released from the
holdback agreements of paragraph (A) above. The “Closing
Price” means, for any
date, the price determined by the first of the following clauses
that applies:  (a) if the Common Stock is then listed or
quoted on the New York Stock Exchange, the NYSE MKT, the NASDAQ
Global Select Market, the NASDAQ Global Market or the NASDAQ
Capital Market or any other national securities exchange, the
closing price per share of the Common Stock for such date (or the
nearest preceding date) on the primary eligible market or exchange
on which the Common Stock is then listed or quoted; (b) if prices
for the Common Stock are then quoted on the OTC Bulletin Board or
any tier of the OTC Markets, the closing bid price per share of the
Common Stock for such date (or the nearest preceding date) so
quoted; or (c) if prices for the Common Stock are then reported in
the “Pink Sheets” published by the National Quotation
Bureau Incorporated (or a similar organization or agency succeeding
to its functions of reporting prices), the most recent closing bid
price per share of the Common Stock so
reported.

 

4. Registration Procedures for
Registrable Securities. The Company will keep each Holder
reasonably advised as to the filing and effectiveness of the
Registration Statement. At its expense with respect to the
Registration Statement, the Company will:

(a) prepare and file
with the Commission with respect to the Registrable Securities, a
Registration Statement on Form S-1, or any other form for which the
Company then qualifies or which counsel for the Company shall deem
appropriate and which form shall be available for the sale of the
Registrable Securities in accordance with the intended methods of
distribution thereof, and use its commercially reasonable efforts
to cause such Registration Statement to become effective and shall
remain effective for a period of one year or for such shorter
period ending on the earlier to occur of (i) the date as of which
all of the Holders as selling stockholders thereunder may sell all
of the Registrable Securities registered for resale thereon without
restriction pursuant to Rule 144 (or any successor rule thereto)
promulgated under the Securities Act or (ii) the date when all of
the Registrable Securities registered thereunder shall have been
sold (the “Effectiveness Period”).
Thereafter, the Company shall be entitled to withdraw such
Registration Statement and the Purchasers shall have no further
right to offer or sell any of the Registrable Securities registered
for resale thereon pursuant to the respective Registration
Statement (or any prospectus relating thereto);

 

10

 

(b) if the Registration
Statement is subject to review by the Commission, respond in a
commercially reasonable manner to all comments and diligently
pursue resolution of any comments to the satisfaction of the
Commission;

(c) prepare and file
with the Commission such amendments and supplements to such
Registration Statement as may be necessary to keep such
Registration Statement effective during the Effectiveness
Period;

(d) furnish, without
charge, to each Holder of Registrable Securities covered by such
Registration Statement (i) a reasonable number of copies of such
Registration Statement (including any exhibits thereto other than
exhibits incorporated by reference), each amendment and supplement
thereto as such Holder may reasonably request, (ii) such number of
copies of the prospectus included in such Registration Statement
(including each preliminary prospectus and any other prospectus
filed under Rule 424 of the Securities Act) as such Holders may
reasonably request, in conformity with the requirements of the
Securities Act, and (iii) such other documents as such Holder may
require to consummate the disposition of the Registrable Securities
owned by such Holder, but only during the Effectiveness
Period;

(e) use its
commercially reasonable efforts to register or qualify such
registration under such other applicable securities laws of such
jurisdictions as any Holder of Registrable Securities covered by
such Registration Statement reasonably requests and as may be
necessary for the marketability of the Registrable Securities (such
request to be made by the time the applicable Registration
Statement is deemed effective by the Commission) and do any and all
other acts and things necessary to enable such Holder to consummate
the disposition in such jurisdictions of the Registrable Securities
owned by such Holder; provided, that the Company
shall not be required to (i) qualify generally to do business in
any jurisdiction where it would not otherwise be required to
qualify but for this paragraph, (ii) subject itself to taxation in
any such jurisdiction, or (iii) consent to general service of
process in any such jurisdiction.

(f) notify each Holder
of Registrable Securities, the disposition of which requires
delivery of a prospectus relating thereto under the Securities Act,
of the happening of any event (as promptly as practicable after
becoming aware of such event), which comes to the Company’s
attention, that will after the occurrence of such event cause the
prospectus included in such Registration Statement, if not amended
or supplemented, to contain an untrue statement of a material fact
or an omission to state a material fact required to be stated
therein or necessary to make the statements therein not misleading
and the Company shall promptly thereafter prepare and furnish to
such Holder a supplement or amendment to such prospectus (or
prepare and file appropriate reports under the Exchange Act) so
that, as thereafter delivered to the purchasers of such Registrable
Securities, such prospectus shall not contain an untrue statement
of a material fact or omit to state any material fact required to
be stated therein or necessary to make the statements therein not
misleading, unless suspension of the use of such prospectus
otherwise is authorized herein or in the event of a Blackout
Period, in which case no supplement or amendment need be furnished
(or Exchange Act filing made) until the termination of such
suspension or Blackout Period;

 

11

 

(g) comply, and
continue to comply during the Effectiveness Period, in all material
respects with the Securities Act and the Exchange Act and with all
applicable rules and regulations of the Commission with respect to
the disposition of all securities covered by such Registration
Statement;

(h) as promptly as
practicable after becoming aware of such event, notify each Holder
of Registrable Securities being offered or sold pursuant to the
Registration Statement of the issuance by the Commission of any
stop order or other suspension of effectiveness of the Registration
Statement;

(i) use
its commercially reasonable efforts to cause all the Registrable
Securities covered by the Registration Statement to be quoted on
such Approved Market on which securities of the same class or
series issued by the Company are then listed or
traded;

(j) provide a transfer
agent and registrar, which may be a single entity, for the shares
of Common Stock at all times;

(k) if requested by the
Holders, cooperate with the Holders to facilitate the timely
preparation and delivery of certificates representing Registrable
Securities to be delivered to a transferee pursuant to the
Registration Statement, which certificates shall be free, to the
extent permitted by applicable law, of all restrictive legends, and
to enable such Registrable Securities to be in such denominations
and registered in such names as any such Holders may
request;

(l) during the
Effectiveness Period, refrain from bidding for or purchasing any
Common Stock or any right to purchase Common Stock or attempting to
induce any person to purchase any such security or right if such
bid, purchase or attempt would in any way limit the right of the
Holders to sell Registrable Securities by reason of the limitations
set forth in Regulation M of the Exchange Act; and

(m) take all other
reasonable actions necessary to expedite and facilitate the
disposition by the Holders of the Registrable Securities pursuant
to the Registration Statement.

5. Suspension of Offers and Sales.
Each Holder agrees that, upon receipt of any notice from the
Company of the happening of any event of the kind described in
Section 4(f) hereof or of the commencement of a Blackout Period,
such Holder shall discontinue the disposition of Registrable
Securities included in the Registration Statement until such
Holder’s receipt of the copies of the supplemented or amended
prospectus contemplated by Section 4(f) hereof or notice of the end
of the Blackout Period, and, if so directed by the Company, such
Holder shall deliver to the Company (at the Company’s
expense) all copies (including, without limitation, any and all
drafts), other than permanent file copies, then in such
Holder’s possession, of the prospectus covering such
Registrable Securities current at the time of receipt of such
notice.

 

12

 

6. Registration Expenses. The
Company shall pay all expenses in connection with any registration
obligation provided herein, including, without limitation, all
registration, filing, stock exchange fees, printing expenses, all
fees and expenses of complying with applicable securities laws, and
the fees and disbursements of counsel for the Company and of its
independent accountants; provided, that, in any
registration, each party shall pay for its own underwriting
discounts and commissions and transfer taxes. Except as provided in
this Section and Section 9, the Company shall not be responsible
for the expenses of any attorney or other advisor employed by a
Holder.

7. Assignment of Rights. No Holder
may assign its rights under this Agreement to any party without the
prior written consent of the Company; provided, however, that any Holder may
assign its rights under this Agreement without such consent to a
Permitted Assignee as long as (a) such transfer or assignment is
effected in accordance with applicable securities laws; (b) such
transferee or assignee agrees in writing to become subject to the
terms of this Agreement; and (c) such Holder notifies the Company
in writing of such transfer or assignment, stating the name and
address of the transferee or assignee and identifying the
Registrable Securities with respect to which such rights are being
transferred or assigned.

8. Information by Holder. A Holder
with Registrable Securities included in any registration shall
furnish to the Company such information regarding itself, the
Registrable Securities held by it, and the intended method of
disposition of such securities as shall be required in order to
comply with any applicable law or regulation in connection with the
registration of such Holder’s Registrable Securities or any
qualification or compliance with respect to such Holder’s
Registrable Securities and referred to in this Agreement. A form of
Selling Stockholder Questionnaire is attached as Exhibit A hereto
for such purposes.

9. Indemnification.

(a) In the event of the
offer and sale of Registrable Securities under the Securities Act,
the Company shall, and hereby does, indemnify and hold harmless, to
the fullest extent permitted by law, each Holder, its directors,
officers, partners, each other person who participates as an
underwriter in the offering or sale of such securities, and each
other person, if any, who controls or is under common control with
such Holder or any such underwriter within the meaning of Section
15 of the Securities Act, against any losses, claims, damages or
liabilities, joint or several, and expenses to which the Holder or
any such director, officer, partner or underwriter or controlling
person may become subject under the Securities Act, the Exchange
Act, or any other federal or state law, insofar as such losses,
claims, damages, liabilities or expenses (or actions or
proceedings, whether commenced or threatened, in respect thereof)
arise out of or are based upon any untrue statement of any material
fact contained in any registration statement prepared and filed by
the Company under which Registrable Securities were registered
under the Securities Act, any preliminary prospectus, final
prospectus or summary prospectus contained therein, or any
amendment or supplement thereto, or any omission to state therein a
material fact required to be stated or necessary to make the
statements therein in light of the circumstances in which they were
made not misleading, or any violation or alleged violation of the
Securities Act, the Exchange Act, any state securities law or any
rule or regulation promulgated under the Securities Act, the
Exchange Act or any state securities law in connection with this
Agreement; and the Company shall reimburse the Holder, and each
such director, officer, partner, underwriter and controlling person
for any legal or any other expenses reasonably incurred by them in
connection with investigating, defending or settling any such loss,
claim, damage, liability, action or proceeding; provided, that such indemnity
agreement found in this Section 9(a) shall in no event exceed the
net proceeds from the PPO received by the Company; and provided further, that the
Company shall not be liable in any such case (i) to the extent that
any such loss, claim, damage, liability (or action or proceeding in
respect thereof) or expense arises out of or is based upon an
untrue statement in or omission from such registration statement,
any such preliminary prospectus, final prospectus, summary
prospectus, amendment or supplement in reliance upon and in
conformity with written information furnished to the Company by the
Holder specifically for use in the preparation thereof or (ii) if
the person asserting any such loss, claim, damage, liability (or
action or proceeding in respect thereof) who purchased the
Registrable Securities that are the subject thereof did not receive
a copy of the preliminary prospectus or the final prospectus (or
the final prospectus as amended or supplemented) at or prior to the
written confirmation of the sale of such Registrable Securities to
such person because of the failure of such Holder or underwriter to
so provide such preliminary or final prospectus and the untrue
statement or omission of a material fact made in such preliminary
prospectus was corrected in the amended preliminary or final
prospectus (or the final prospectus as amended or supplemented).
Such indemnity shall remain in full force and effect regardless of
any investigation made by or on behalf of the Holders, or any such
director, officer, partner, underwriter or controlling person and
shall survive the transfer of such shares by the
Holder.

 

13

 

(b) As a condition to
including Registrable Securities in any registration statement
filed pursuant to this Agreement, each Holder agrees to be bound by
the terms of this Section 9 and to indemnify and hold harmless, to
the fullest extent permitted by law, the Company, its directors and
officers, and each other person, if any, who controls the Company
within the meaning of Section 15 of the Securities Act, against any
losses, claims, damages or liabilities, joint or several, to which
the Company or any such director or officer or controlling person
may become subject under the Securities Act, the Exchange Act, or
any other federal or state law, to the extent arising out of or
based solely upon: (x) such Holder’s failure to comply with
the prospectus delivery requirements of the Securities Act or (y)
any untrue or alleged untrue statement of a material fact contained
in any registration statement, any prospectus, or any form of
prospectus, or in any amendment or supplement thereto or in any
preliminary prospectus, or arising out of or relating to any
omission or alleged omission of a material fact required to be
stated therein or necessary to make the statements therein not
misleading (i) to the extent, but only to the extent, that such
untrue statement or omission is contained in any information so
furnished in writing by such Holder to the Company specifically for
inclusion in the registration statement or such prospectus or (ii)
to the extent that (1) such untrue statements or omissions are
based solely upon information regarding such Holder furnished in
writing to the Company by such Holder expressly for use therein, or
to the extent that such information relates to such Holder or such
Holder’s proposed method of distribution of Registrable
Securities and was reviewed and expressly approved in writing by
such Holder expressly for use in the Registration Statement, such
prospectus or such form of prospectus or in any amendment or
supplement thereto or (2) in the case of an occurrence of an event
of the type specified in Section 4(f) hereof, the use by such
Holder of an outdated or defective prospectus after the Company has
notified such Holder in writing that the prospectus is outdated or
defective and prior to the receipt by such Holder of the advice
contemplated in Section 4(f). In no event shall the liability of
any selling Holder hereunder be greater in amount than the dollar
amount of the net proceeds received by such Holder upon the sale of
the Registrable Securities giving rise to such indemnification
obligation.

 

14

 

(c) Promptly after
receipt by an indemnified party of notice of the commencement of
any action or proceeding involving a claim referred to in this
Section (including any governmental action), such indemnified party
shall, if a claim in respect thereof is to be made against an
indemnifying party, give written notice to the indemnifying party
of the commencement of such action; provided, that the failure of
any indemnified party to give notice as provided herein shall not
relieve the indemnifying party of its obligations under this
Section, except to the extent that the indemnifying party is
actually prejudiced by such failure to give notice. In case any
such action is brought against an indemnified party, unless in the
reasonable judgment of counsel to such indemnified party a conflict
of interest between such indemnified and indemnifying parties may
exist or the indemnified party may have defenses not available to
the indemnifying party in respect of such claim, the indemnifying
party shall be entitled to participate in and to assume the defense
thereof, with counsel reasonably satisfactory to such indemnified
party and, after notice from the indemnifying party to such
indemnified party of its election so to assume the defense thereof,
the indemnifying party shall not be liable to such indemnified
party for any legal or other expenses subsequently incurred by the
latter in connection with the defense thereof, unless in such
indemnified party’s reasonable judgment a conflict of
interest between such indemnified and indemnifying parties arises
in respect of such claim after the assumption of the defenses
thereof or the indemnifying party fails to defend such claim in a
diligent manner, other than reasonable costs of investigation.
Neither an indemnified nor an indemnifying party shall be liable
for any settlement of any action or proceeding effected without its
consent. No indemnifying party shall, without the consent of the
indemnified party, consent to entry of any judgment or enter into
any settlement, which does not include as an unconditional term
thereof the giving by the claimant or plaintiff to such indemnified
party of a release from all liability in respect of such claim or
litigation. Notwithstanding anything to the contrary set forth
herein, and without limiting any of the rights set forth above, in
any event any party shall have the right to retain, at its own
expense, counsel with respect to the defense of a
claim.

(d) If an indemnifying
party does or is not permitted to assume the defense of an action
pursuant to Sections 9(c) or in the case of the expense
reimbursement obligation set forth in Sections 9(a) and (b), the
indemnification required by Sections 9(a) and 9(b) shall be made by
periodic payments of the amount thereof during the course of the
investigation or defense, as and when bills received or expenses,
losses, damages, or liabilities are incurred.

(e) If the
indemnification provided for in Section 9(a) or 9(b) is held by a
court of competent jurisdiction to be unavailable to an indemnified
party with respect to any loss, liability, claim, damage or expense
referred to herein, the indemnifying party, in lieu of indemnifying
such indemnified party hereunder, shall (i) contribute to the
amount paid or payable by such indemnified party as a result of
such loss, liability, claim, damage or expense as is appropriate to
reflect the proportionate relative fault of the indemnifying party
on the one hand and the indemnified party on the other (determined
by reference to, among other things, whether the untrue or alleged
untrue statement of a material fact or omission relates to
information supplied by the indemnifying party or the indemnified
party and the parties’ relative intent, knowledge, access to
information and opportunity to correct or prevent such untrue
statement or omission), or (ii) if the allocation provided by
clause (i) above is not permitted by applicable law or provides a
lesser sum to the indemnified party than the amount hereinafter
calculated, not only the proportionate relative fault of the
indemnifying party and the indemnified party, but also the relative
benefits received by the indemnifying party on the one hand and the
indemnified party on the other, as well as any other relevant
equitable considerations. No indemnified party guilty of fraudulent
misrepresentation (within the meaning of Section 11(f) of the
Securities Act) shall be entitled to contribution from any
indemnifying party who was not guilty of such fraudulent
misrepresentation.

 

15

 

(f) Other Indemnification.
Indemnification similar to that specified in this Section (with
appropriate modifications) shall be given by the Company and each
Holder of Registrable Securities with respect to any required
registration or other qualification of securities under any federal
or state law or regulation or governmental authority other than the
Securities Act.

10. Rule
144. With a view to making
available to the Holders the benefits of Rule 144 and any other
rule or regulation of the Commission that may at any time permit
the Holders to sell the Registrable Securities to the public
without registration, the Company agrees: (i) to make and keep
public information available as those terms are understood in Rule
144, (ii) to file with the Commission in a timely manner all
reports and other documents required to be filed by an issuer of
securities registered under the Securities Act or the Exchange Act
pursuant to Rule 144, (iii) as long as any Holder owns any
Registrable Securities, to furnish in writing upon such
Holder’s request a written statement by the Company that it
has complied with the reporting requirements of Rule 144 and of the
Securities Act and the Exchange Act, and to furnish to such Holder
a copy of the most recent annual or quarterly report of the
Company, and such other reports and documents so filed by the
Company as may be reasonably requested in availing such Holder of
any rule or regulation of the Commission permitting the selling of
any such Registrable Securities without registration and (iv)
undertake any additional actions commercially reasonably necessary
to maintain the availability of the use of Rule
144.

11. Independent Nature of Each
Purchaser’s Obligations and Rights. The obligations of
each Purchaser under this Agreement are several and not joint with
the obligations of any other Purchaser, and each Purchaser shall
not be responsible in any way for the performance of the
obligations of any other Purchaser under this Agreement. Nothing
contained herein and no action taken by any Purchaser pursuant
hereto, shall be deemed to constitute such Purchasers as a
partnership, an association, a joint venture, or any other kind of
entity, or create a presumption that the Purchasers are in any way
acting in concert or as a group with respect to such obligations or
the transactions contemplated by this Agreement. Each Purchaser
shall be entitled to independently protect and enforce its rights,
including without limitation the rights arising out of this
Agreement, and it shall not be necessary for any other Purchaser to
be joined as an additional party in any proceeding for such
purpose.

 

16

 

12. Miscellaneous.

(a) Governing
Law. This Agreement shall be governed by and construed in
accordance with the laws of the United States of America and the
State of New York, both substantive and remedial, without regard to
New York conflicts of law principles. Any judicial proceeding brought against either of
the parties to this Agreement or any dispute arising out of this
Agreement or any matter related hereto shall be brought in the
courts of the State of New York, New York County, or in the United
States District Court for the Southern District of New York and, by
its execution and delivery of this Agreement, each party to this
Agreement accepts the jurisdiction of such courts. The foregoing
consent to jurisdiction shall not be deemed to confer rights on any
person other than the parties to this
Agreement.

(b) Remedies. In the event of a
breach by the Company or by a Holder of any of their respective
obligations under this Agreement, each Holder or the Company, as
the case may be, in addition to being entitled to exercise all
rights granted by law and under this Agreement, including recovery
of damages, shall be entitled to specific performance of its rights
under this Agreement. The Company and each Holder agree that
monetary damages would not provide adequate compensation for any
losses incurred by reason of a breach by it of any of the
provisions of this Agreement and hereby further agrees that, in the
event of any action for specific performance in respect of such
breach, it shall not assert or shall waive the defense that a
remedy at law would be adequate.

(c) Successors and Assigns. Except
as otherwise provided herein, the provisions hereof shall inure to
the benefit of, and be binding upon, the successors, Permitted
Assignees, executors and administrators of the parties
hereto.

(d) No Inconsistent Agreements. The
Company has not entered, as of the date hereof, and shall not
enter, on or after the date of this Agreement, into any agreement
with respect to its securities that would have the effect of
impairing the rights granted to the Holders in this Agreement or
otherwise conflicts with the provisions hereof.

(e) Entire Agreement. This
Agreement constitutes the full and entire understanding and
agreement between the parties with regard to the subjects
hereof.

(f) Notices, etc. All notices or
other communications which are required or permitted under this
Agreement shall be in writing and sufficient if delivered by hand,
by facsimile transmission, by registered or certified mail, postage
pre-paid, by electronic mail, or by courier or overnight carrier,
to the persons at the addresses set forth below (or at such other
address as may be provided hereunder), and shall be deemed to have
been delivered as of the date so delivered:

 

17

 

If to
the Company to:

 

Adgero
Biopharmaceuticals Holdings, Inc.

301 N.
Harrison St., Suite 9F #459,

Princeton, NJ
08540

E-mail:
frankgpilkiewicz@comcast.net

 

with
copy to:

 

Lowenstein Sandler
LLP

1251
Avenue of the Americas

New
York, NY 10020

Attn:
Steven M. Skolnick, Esq.

Facsimile:
(973) 597-2477

 

If to
the Purchasers:

 

To each
Purchaser at the address set forth on the signature page hereto or
at such other address as any party shall have furnished to the
other parties in writing.

 

(g) Delays or Omissions. No delay
or omission to exercise any right, power or remedy accruing to any
Holder, upon any breach or default of the Company under this
Agreement, shall impair any such right, power or remedy of such
Holder nor shall it be construed to be a waiver of any such breach
or default, or an acquiescence therein, or of any similar breach or
default thereunder occurring; nor shall any waiver of any single
breach or default be deemed a waiver of any other breach or default
theretofore or thereafter occurring. Any waiver, permit, consent or
approval of any kind or character on the part of any Holder of any
breach or default under this Agreement, or any waiver on the part
of any Holder of any provisions or conditions of this Agreement,
must be in writing and shall be effective only to the extent
specifically set forth in such writing. All remedies, either under
this Agreement, or by law or otherwise afforded to any holder,
shall be cumulative and not alternative.

(h) Counterparts. This Agreement
may be executed in any number of counterparts, each of which shall
be enforceable against the parties actually executing such
counterparts, and all of which together shall constitute one
instrument. In the event that any signature is delivered by
facsimile transmission or electronic transmission via .PDF file,
such signature shall create a valid and binding obligation of the
party executing (or on whose behalf such signature is executed)
with the same force and effect as if such facsimile or electronic
signature page were an original thereof.

(i) Severability. In the case any
provision of this Agreement shall be invalid, illegal or
unenforceable, the validity, legality and enforceability of the
remaining provisions shall not in any way be affected or impaired
thereby.

(j) Amendments. The provisions of
this Agreement may be amended at any time and from time to time,
and particular provisions of this Agreement may be waived, with and
only with an agreement or consent in writing signed by the Company
and the Majority Holders. The Purchasers acknowledge that by the
operation of this Section, the Majority Holders may have the right
and power to diminish or eliminate all rights of the Purchasers
under this Agreement.

[SIGNATURE
PAGES FOLLOW]

 

18

 

This
Registration Rights Agreement is hereby executed as of the date
first above written.

COMPANY:

ADGERO
BIOPHARMACEUTICALS

HOLDINGS,
INC.

 

 

By:
_________________________________
                                                              

Name:
Frank Pilkiewicz

Title:
Chief Executive Officer

 

EACH
PURCHASER’S SIGNATURE TO THE SUBSCRIPTION AGREEMENT DATED OF
EVEN DATE HEREWITH SHALL CONSTITUTE THE PURCHASER’S SIGNATURE
TO THIS REGISTRATION RIGHTS AGREEMENT.

 

 

19

 

This
Registration Rights Agreement is hereby executed as of the date
first above written.

Holder:

	

Entity:

 

Name of Entity: _____________________

 

By                                                                    

      Name
and Title: ________________

      Address:
________________

                    ________________

       Email:
____________________

 

	

       Number of Shares:
________________

 

	
 

	

Individual:

 

By                                                                    

      Name:
________________

      Address:
________________

                    ________________

      Email:
___________________

      Number of Shares:
________________

 

	
 

	
 

 

 

20

 

 

Exhibit
A

Selling
Stockholder Questionnaire

[See
Attached.]

 

 

 

 

21

 

 

WAIVER AND AMENDMENT OF REGISTRATION RIGHTS AGREEMENT

This
Waiver and Amendment of Registration Rights Agreement is made and
entered into effective as of the Effective Date (as defined below)
between Adgero Biopharmaceuticals Holdings, Inc., a Delaware
corporation (the “Company”), and the other parties
to the Registration Rights Agreement (the “Agreement”) dated April 8, 2016,
consisting of investors in the PPO (as defined below), certain
bridge note investors who exchanged their bridge notes for
securities identical to those sold in the PPO, and holders of
replacement warrants (“Replacement Warrants”) that were
issued in exchange for warrants to purchase shares of common stock
of Adgero Biopharmaceuticals, Inc., a Delaware corporation, in
connection with the Merger (as defined in the Agreement) (each, a
“Purchaser” and
collectively, the “Purchasers”).

RECITALS:

WHEREAS, the
Company has offered in compliance with Rule 506(b) of Regulation D
of the Securities Act, to accredited investors in a private
placement transaction with Aegis Capital Corp. acting as the
placement agent (the “PPO”), units of its securities,
each consisting of: (i) one (1) share of Common Stock (the
“Investor
Shares”), and (ii) a five-year warrant (the
“Investor
Warrants”) to purchase one (1) share of Common Stock
at an initial exercise price of $5.00 per Share;

WHEREAS, the
initial closing of the PPO occurred on or about April 8, 2016, four
subsequent closings of the PPO occurred on or about April 29, 2016,
May 31, 2016, June 9, 2016, and July 8, 2016, and the final closing
of the PPO occurred on July 29, 2016;

WHEREAS, in
connection with the PPO, the Company agreed to provide certain
registration rights related to the Investor Shares and the shares
of Common Stock issuable upon exercise of the Investor Warrants and
the Replacement Warrants, including the filing of a Registration
Statement on Form S-1, or other applicable form, relating to the
resale by the Holders of all of the Registrable Securities not
later than the Registration Filing Date;

WHEREAS, the
occurrence of a Registration Event entitles the Holders to certain
liquidated damages pursuant to Section 3(d) of the
Agreement;

WHEREAS, Section
12(j) of the Agreement provides that the provisions of the
Agreement may be amended at any time and from time to time, and
particular provisions of the Agreement may be waived, with and only
with an agreement or consent in writing signed by the Company and
the Majority Holders, and the parties hereto wish to make clear
that any liquidated damages that have accrued through the Effective
Date, or that will continue to accrue through the Registration
Filing Date (as defined below) pursuant to the Agreement, will be
waived.

NOW,
THEREFORE, in consideration of the mutual promises,
representations, warranties, covenants, and conditions set forth
herein, the parties mutually agree as follows:

1. Definitions. All capitalized
terms used but not specifically defined herein shall have the same
meanings given such terms in the Agreement.

 

22

 

 

2. Amendment.  The following
terms, whether used herein or in the Agreement, shall be deemed to
be amended to read as follows:

“Registration Filing Date“
means the date on which the Registration Statement is filed with
the Commission.

3. Waiver. The Holders waive any
claims and rights to liquidated damages that have arisen under the
Agreement prior to the Effective Date hereof or that will continue
to accrue through the Registration Filing Date (as defined
herein).

4. Miscellaneous.

(a) Governing Law. This Amendment
shall be governed by and construed in accordance with the laws of
the United States of America and the State of New York, both
substantive and remedial, without regard to New York conflicts of
law principles.

(b) Successors and Assigns. Except
as otherwise provided herein, the provisions hereof shall inure to
the benefit of, and be binding upon, all Purchasers, and the
successors, Permitted Assignees, executors and administrators of
the parties hereto.

(c) Counterparts. This Amendment
may be executed in any number of counterparts, each of which shall
be enforceable against the parties actually executing such
counterparts, and all of which together shall constitute one
instrument. In the event that any signature is delivered by
facsimile transmission or electronic transmission via .PDF file,
such signature shall create a valid and binding obligation of the
party executing (or on whose behalf such signature is executed)
with the same force and effect as if such facsimile or electronic
signature page were an original thereof.

(d) Severability. In the case any
provision of this Waiver and Amendment shall be invalid, illegal or
unenforceable, the validity, legality and enforceability of the
remaining provisions shall not in any way be affected or impaired
thereby. Any inconsistency between the provisions of this Waiver
and Amendment and the Agreement shall be resolved in favor of the
provisions of this Waiver and Amendment. In all other respects, the
Agreement shall remain in full force and effect.

(e) Effective Date. The provisions
of this Waiver and Amendment shall become effective and binding
upon all Purchasers immediately upon execution by Purchasers
constituting the Majority Holders (the “Effective Date”).

 

 

[Signature Pages Follow]

 

23

 

This
Waiver and Amendment of Registration Rights Agreement is hereby
executed as of this [__]th day of October
2016.

	

 

	

COMPANY:

ADGERO
BIOPHARMACEUTICALS HOLDINGS, INC.

  

	

 

	

 

	

 

	

 

	

 

	
 

	
By:  

	
 

	

 

	

 

	

Name:    

	
Frank G.
Pilkiewicz

	

 

	

 

	

Title:

	Chief Executive
Officer	

 

 [Signature Page to Waiver]

 

 

24

 

 

This
Waiver and Amendment of Registration Rights Agreement is hereby
executed as of this [__]th day of October
2016.

 

PURCHASER OR HOLDER:

	

Entity:

Name of Entity: _____________________

 

By                                                                    

   
  Name and Title: ________________

  
   Address: ________________

                   ________________

      Email:
____________________

 

	

      Number of Shares:
________________

      Number of Warrants:
________________

 

	

 

 

 

Individual:

 

 

    
_________________________________

    
Name: ________________

     Address:
________________

                   ________________

     Email:
___________________

     Number of Shares:
________________

     Number of Warrants:
________________

 

 

 

 

 

 [Signature
Page to Waiver]

 

 

 

 

 

 

 25Blueprint

 

Exhibit 4.5

 

Warrant
Certificate No. ___

 

 

NEITHER
THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES
ISSUABLE UPON THE EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“ACT”), OR ANY STATE SECURITIES LAWS, AND NEITHER SUCH
SECURITIES NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, ASSIGNED
OR OTHERWISE TRANSFERRED UNLESS (1) A REGISTRATION STATEMENT WITH
RESPECT THERETO IS EFFECTIVE UNDER THE ACT AND ANY APPLICABLE STATE
SECURITIES LAWS, OR (2) AN EXEMPTION FROM SUCH REGISTRATION EXISTS
AND THE COMPANY RECEIVES AN OPINION OF COUNSEL TO THE HOLDER OF
SUCH SECURITIES, WHICH COUNSEL AND OPINION ARE SATISFACTORY TO THE
COMPANY, THAT SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED,
ASSIGNED OR TRANSFERRED IN THE MANNER CONTEMPLATED WITHOUT AN
EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT OR APPLICABLE STATE
SECURITIES LAWS.

 

	
 Effective Date: [
], 2016

	
 Void After: [ ],
2021

 

 

 

ADGERO BIOPHARMACEUTICALS HOLDINGS,
INC.

 

WARRANT
TO PURCHASE COMMON STOCK

 

Adgero Biopharmaceuticals Holdings, Inc., a Delaware corporation
(the “Company”),
for value received on [ ], 2016 (the “Effective Date”), hereby issues to
[ ] (the “Holder” or “Warrant Holder”) this Warrant (the
“Warrant”) to
purchase, [ ] shares (each
such share as from time to time adjusted as hereinafter provided
being a “Warrant
Share” and all such shares being the
“Warrant
Shares”) of the Company’s Common Stock (as
defined below), at the Exercise Price (as defined below), as
adjusted from time to time as provided herein, on or before [ ],
2021 (the “Expiration
Date”), all subject to the following terms and
conditions. This Warrant is one of a series of warrants of like
tenor that have been issued in connection with the Company’s
private offering solely to accredited investors of units commenced
on or about August __, 2016 in accordance with, and subject to, the
terms and conditions described in those certain Subscription
Agreements, as the same may be amended and supplemented from time
to time (each a “Subscription
Agreement” and collectively, the “Subscription
Agreements”).

As used
in this Warrant, (i) “Business Day” means any day other
than Saturday, Sunday or any other day on which commercial banks in
the City of New York, New York, are authorized or required by law
or executive order to close; (ii) “Common Stock” means the common
stock of the Company, par value $0.0001 per share, including any
securities issued or issuable with respect thereto or into which or
for which such shares may be exchanged for, or converted into,
pursuant to any stock dividend, stock split, stock combination,
recapitalization, reclassification, reorganization or other similar
event; (iii) “Exercise
Price” means $5.00
per share of Common Stock, subject to adjustment as provided
herein; (iv) “Trading
Day” means any day on which the Common Stock is traded
(or available for trading) on its principal trading
market; (v) “Affiliate” means any person that, directly or
indirectly, through one or more intermediaries, controls, is
controlled by, or is under common control with, a person, as such
terms are used and construed in Rule 144 promulgated under the
Securities Act of 1933, as amended (the “Securities
Act”) and (vi)
“Warrantholders”
means the holders of Warrants issued pursuant to the Subscription
Agreements.

 

 

1

 

 

1. DURATION AND EXERCISE OF
WARRANTS

 

(a)    Exercise
Period. The Holder may exercise
this Warrant in whole or in part on any Business Day on or before
5:00 P.M., Eastern Time, on the Expiration Date, at which time this
Warrant shall become void and of no value.

 

(b)    Exercise
Procedures.

 

(i)           While
this Warrant remains outstanding and exercisable in accordance with
Section 1(a), in addition to the manner set forth in Section
1(b)(ii) below, the Holder may exercise this Warrant in whole or in
part at any time and from time to time by:

 

(A)           delivery
to the Company of a duly executed copy of the Notice of Exercise
attached as Exhibit A;

 

(B)           surrender
of this Warrant to the Secretary of the Company at its principal
offices or at such other office or agency as the Company may
specify in writing to the Holder; and

 

(C)           payment
of the then-applicable Exercise Price per share multiplied by the
number of Warrant Shares being purchased upon exercise of the
Warrant (such amount, the “Aggregate Exercise
Price”) made in the form
of cash, or by certified check, bank draft or money order payable
in lawful money of the United States of America or in the form of a
Cashless Exercise to the extent permitted in Section 1(b)(ii)
below.

 

(ii)           In
addition to the provisions of Section 1(b)(i) above, if at any time
after the date that is 150 days after a registration statement is
actually filed with the Securities and Exchange Commission (the
“SEC”) covering the resale of the Warrant Shares
by the Holder, such registration statement covering the resale of
the Warrant Shares by the Holder is not effective with the
SEC, the Holder may, in its sole discretion, exercise
all or any part of the Warrant in a “cashless” or
“net-issue” exercise (a “Cashless
Exercise”) by delivering
to the Company (1) the Notice of Exercise and (2) the original
Warrant, pursuant to which the Holder shall surrender the right to
receive upon exercise of this Warrant, a number of Warrant Shares
having a value (as determined below) equal to the Aggregate
Exercise Price, in which case, the number of Warrant Shares to be
issued to the Holder upon such exercise shall be calculated using
the following formula:

 

 

2

 

 

X              =              Y
* (A - B)

       A

 

	
 

	
with:

	
X=

	
 the number of Warrant Shares to be issued to the
Holder

	
 

	
 

	
 

	
 

	
 

	
 

	
Y=

	
 the
number of Warrant Shares with respect to which the Warrant is being
exercised

	
 

	
 

	
 

	
 

	
 

	
 

	
A=

	
 the
fair value per share of Common Stock on the date of exercise of
this Warrant

	
 

	
 

	
 

	
 

	
 

	
 

	
B=

	
 the then-current Exercise Price of the
Warrant

  

Solely for the purposes of this paragraph,
“fair
value” per share of
Common Stock shall mean the average Closing Price (as defined
below) per share of Common Stock for the twenty (20) trading days
immediately preceding the date on which the Notice of Exercise is
deemed to have been sent to the Company. “Closing
Price” means, for any
date, the price determined by the first of the following clauses
that applies:  (a) if the Common Stock is then listed or
quoted on the New York Stock Exchange, the NYSE MKT, the NASDAQ
Global Select Market, the NASDAQ Global Market or the NASDAQ
Capital Market or any other national securities exchange, the
closing price per share of the Common Stock for such date (or the
nearest preceding date) on the primary eligible market or exchange
on which the Common Stock is then listed or quoted; (b) if prices
for the Common Stock are then quoted on the OTC Bulletin Board or
any tier of the OTC Markets, the closing bid price per share of the
Common Stock for such date (or the nearest preceding date) so
quoted; or (c) if prices for the Common Stock are then reported in
the “Pink Sheets” published by the National Quotation
Bureau Incorporated (or a similar organization or agency succeeding
to its functions of reporting prices), the most recent closing bid
price per share of the Common Stock so reported. If the Common
Stock is not publicly traded as set forth above, the “fair
value” per share of Common Stock shall be reasonably and in
good faith determined by the Board of Directors of the Company as
of the date which the Notice of Exercise is deemed to have been
sent to the Company.

 

Notwithstanding
the foregoing, provided that a registration statement (including
any post-effective amendment) covering the resale of the Warrant
Shares by the Holder has (x) been declared effective by the SEC and
(y) has been effective for an aggregate period of one year, any
Cashless Exercise right hereunder shall thereupon
terminate.

 

For
purposes of Rule 144 promulgated under the Securities Act, it is
intended, understood and acknowledged that the Warrant Shares
issued in a cashless exercise transaction shall be deemed to have
been acquired by the Holder, and the holding period for such shares
shall be deemed to have commenced, on the date this Warrant was
originally issued.

 

(iii)           Upon
the exercise of this Warrant in compliance with the provisions of
this Section 1(b), and except as limited pursuant to the last
paragraph of Section 1(b)(ii), the Company shall promptly issue and
cause to be delivered to the Holder a certificate for the Warrant
Shares purchased by the Holder. Each exercise of this Warrant shall
be effective immediately prior to the close of business on the date
(the “Date of
Exercise”) that the
conditions set forth in Section 1(b) have been satisfied, as the
case may be. On the first Business Day following the date on which
the Company has received each of the Notice of Exercise and the
Aggregate Exercise Price (or notice of a Cashless Exercise in
accordance with Section 1(b)(ii)) (the “Exercise Delivery
Documents”), the Company
shall transmit an acknowledgment of receipt of the Exercise
Delivery Documents to the Company’s transfer agent (the
“Transfer
Agent”). On or before the
third Business Day following the date on which the Company has
received all of the Exercise Delivery Documents (the
“Share
Delivery Date”), the
Company shall (X) provided that the Transfer Agent is participating
in The Depository Trust Company (“DTC”) Fast Automated Securities Transfer
Program, upon the request of the Holder, credit such aggregate
number of shares of Common Stock to which the Holder is entitled
pursuant to such exercise to the Holder’s or its
designee’s balance account with DTC through its Deposit
Withdrawal Agent Commission system, or (Y) if the Transfer Agent is
not participating in the DTC Fast Automated Securities Transfer
Program, issue and dispatch by overnight courier to the address as
specified in the Notice of Exercise, a certificate, registered in
the Company’s share register in the name of the Holder or its
designee, for the number of shares of Common Stock to which the
Holder is entitled pursuant to such exercise. Upon delivery of the
Exercise Delivery Documents, the Holder shall be deemed for all
corporate purposes to have become the holder of record of the
Warrant Shares with respect to which this Warrant has been
exercised, irrespective of the date of delivery of the certificates
evidencing such Warrant Shares.

 

 

3

 

 

(iv)           If
the Company shall fail for any reason or for no reason to issue to
the Holder, within three (3) Business Days of receipt of the
Exercise Delivery Documents, a certificate for the number of shares
of Common Stock to which the Holder is entitled and register such
shares of Common Stock on the Company’s share register or to
credit the Holder’s balance account with DTC for such number
of shares of Common Stock to which the Holder is entitled upon the
Holder’s exercise of this Warrant, and if on or after such
Business Day the Holder purchases (in an open market transaction or
otherwise) shares of Common Stock to deliver in satisfaction of a
sale by the Holder of shares of Common Stock issuable upon such
exercise that the Holder anticipated receiving from the Company (a
“Buy-In”), then the Company shall, (A) pay in cash
to the Holder the amount, if any, by which (x) the Holder’s
total purchase price (including brokerage commissions, if any) for
the shares of Common Stock so purchased (the
“Buy-In
Amount”) plus the amount
paid by the Holder to the Company as the exercise price for the
Warrant Shares exceeds (y) the amount obtained by multiplying (1)
the number of Warrant Shares that the Company was required to
deliver to the Holder in connection with the exercise at issue
times (2) the price at which the sell order giving rise to such
purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Warrant and equivalent
number of Warrant Shares for which such exercise was not honored or
deliver to the Holder the number of shares of Common Stock that
would have been issued had the Company timely complied with its
exercise and delivery obligations hereunder. For example, if the
Holder purchases Common Stock having a total purchase price of
$11,000 to cover a Buy-In with respect to an attempted exercise of
shares of Common Stock, and paid the Company $5,000 as the exercise
price, the Holder’s cash outlay would be a total of $16,000;
and if the aggregate sales price of the shares giving rise to such
Buy-In obligation was $10,000, under clause (A) of the immediately
preceding sentence the Company shall be required to pay the Holder
$6,000. The Holder shall provide the Company written notice
indicating the amounts payable to the Holder in respect of the
Buy-In and, upon request of the Company, evidence of the amount of
such loss. Nothing herein shall limit a Holder’s right to
pursue any other remedies available to it hereunder, at law or in
equity including, without limitation, a decree of specific
performance and/or injunctive relief with respect to the
Company’s failure to timely deliver certificates representing
shares of Common Stock upon exercise of the Warrant as required
pursuant to the terms hereof.

 

 

4

 

 

(c)    Partial
Exercise. This Warrant shall be
exercisable, either in its entirety or, from time to time, for part
only of the number of Warrant Shares referenced by this Warrant. If
this Warrant is submitted in connection with any exercise pursuant
to Section 1 and the number of Warrant Shares represented by this
Warrant submitted for exercise is greater than the actual number of
Warrant Shares being acquired upon such an exercise, then the Company shall as soon as
practicable and in no event later than five (5) Business Days after
any exercise and at its own expense, issue a new Warrant of like
tenor representing the right to purchase the number of Warrant
Shares purchasable immediately prior to such exercise under this
Warrant, less the number of Warrant Shares with respect to which
this Warrant is exercised.

 

(d)    Disputes.
In the case of a dispute as to the determination of the Exercise
Price or the arithmetic calculation of the Warrant Shares, the
Company shall promptly issue to the Holder the number of Warrant
Shares that are not disputed and resolve such dispute in accordance
with Section 16.

 

2. ISSUANCE OF WARRANT SHARES

 

(a)           The
Company covenants that all Warrant Shares will, upon issuance in
accordance with the terms of this Warrant, be (i) duly authorized,
fully paid and non-assessable, and (ii) free from all liens,
charges and security interests, with the exception of claims
arising through the acts or omissions of any Holder and except as
arising from applicable Federal and state securities
laws.

 

(b)           The
Company shall register this Warrant upon records to be maintained
by the Company for that purpose in the name of the record holder of
such Warrant from time to time. The Company may deem and treat the
registered Holder of this Warrant as the absolute owner thereof for
the purpose of any exercise thereof, any distribution to the Holder
thereof and for all other purposes.

 

(c)           The
Company will not, by amendment of its certificate of incorporation,
by-laws or through any reorganization, transfer of assets,
consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance
or performance of any of the terms to be observed or performed
hereunder by the Company, but will at all times in good faith
assist in the carrying out of all the provisions of this Warrant
and in the taking of all action necessary or appropriate in order
to protect the rights of the Holder to exercise this Warrant, or
against impairment of such rights.

 

5

 

3.            ADJUSTMENTS
OF EXERCISE PRICE, NUMBER AND TYPE OF WARRANT
SHARES

 

(a)           The
Exercise Price and the number of shares purchasable upon the
exercise of this Warrant shall be subject to adjustment from time
to time upon the occurrence of certain events described in this
Section 3; provided,
that notwithstanding the provisions of this Section 3, the Company
shall not be required to make any adjustment if and to the extent
that such adjustment would require the Company to issue a number of
shares of Common Stock in excess of its authorized but unissued
shares of Common Stock, less all amounts of Common Stock that have
been reserved for issue upon the conversion of all outstanding
securities convertible into shares of Common Stock and the exercise
of all outstanding options, warrants and other rights exercisable
for shares of Common Stock. If the Company does not have the
requisite number of authorized but unissued shares of Common Stock
to make any adjustment, the Company shall use its commercially best
efforts to obtain the necessary stockholder consent to increase the
authorized number of shares of Common Stock to make such an
adjustment pursuant to this Section 3.

 

(i)           Subdivision
or Combination of Stock. In
case the Company shall at any time subdivide (whether by way of
stock dividend, stock split or otherwise) its outstanding shares of
Common Stock into a greater number of shares, the Exercise Price in
effect immediately prior to such subdivision shall be
proportionately reduced and the number of Warrant Shares shall be
proportionately increased, and conversely, in case the outstanding
shares of Common Stock of the Company shall be combined (whether by
way of stock combination, reverse stock split or otherwise) into a
smaller number of shares, the Exercise Price in effect immediately
prior to such combination shall be proportionately increased and
the number of Warrant Shares shall be proportionately decreased.
The Exercise Price and the Warrant Shares, as so adjusted, shall be
readjusted in the same manner upon the happening of any successive
event or events described in this Section
3(a)(i).

 

(ii)           Dividends
in Stock, Property, Reclassification. If at any time, or from time to time, all of the
holders of Common Stock (or any shares of stock or other securities
at the time receivable upon the exercise of this Warrant) shall
have received or become entitled to receive, without payment
therefore:

 

(A)           any
shares of stock or other securities that are at any time directly
or indirectly convertible into or exchangeable for Common Stock, or
any rights or options to subscribe for, purchase or otherwise
acquire any of the foregoing by way of dividend or other
distribution, or

 

(B)           additional
stock or other securities or property (including cash) by way of
spin-off, split-up, reclassification, combination of shares or
similar corporate rearrangement (other than shares of Common Stock
issued as a stock split or adjustments in respect of which shall be
covered by the terms of Section 3(a)(i) above),

 

then and in each such case, the Exercise Price and the number of
Warrant Shares to be obtained upon exercise of this Warrant shall
be adjusted proportionately, and the Holder hereof shall, upon the
exercise of this Warrant, be entitled to receive, in addition to
the number of shares of Common Stock receivable thereupon, and
without payment of any additional consideration therefor, the
amount of stock and other securities and property (including cash
in the cases referred to above) that such Holder would hold on the
date of such exercise had such Holder been the holder of record of
such Common Stock as of the date on which holders of Common Stock
received or became entitled to receive such shares or all other
additional stock and other securities and property. The Exercise
Price and the Warrant Shares, as so adjusted, shall be readjusted
in the same manner upon the happening of any successive event or
events described in this Section 3(a)(ii).

 

 

6

 

 

(iii)           Reorganization,
Reclassification, Consolidation, Merger or Sale. If any recapitalization,
reclassification or reorganization of the capital stock of the
Company, or any consolidation or merger of the Company with another
corporation, or the sale of all or substantially all of its assets
or other transaction shall be effected in such a way that holders
of Common Stock shall be entitled to receive stock, securities, or
other assets or property (an “Organic
Change”), then, as a condition of
such Organic Change, lawful and adequate provisions shall be made
by the Company whereby the Holder hereof shall thereafter have the
right to purchase and receive (in lieu of the shares of the Common
Stock of the Company immediately theretofore purchasable and
receivable upon the exercise of the rights represented by this
Warrant) such shares of stock, securities or other assets or
property as may be issued or payable with respect to or in exchange
for a number of outstanding shares of such Common Stock equal to
the number of shares of such stock immediately theretofore
purchasable and receivable assuming the full exercise of the rights
represented by this Warrant. In the event of any Organic Change,
appropriate provision shall be made by the Company with respect to
the rights and interests of the Holder of this Warrant to the end
that the provisions hereof (including, without limitation,
provisions for adjustments of the Exercise Price and of the number
of shares purchasable and receivable upon the exercise of this
Warrant and registration rights) shall thereafter be applicable, in
relation to any shares of stock, securities or assets thereafter
deliverable upon the exercise hereof. The Company will not affect
any such consolidation, merger or sale unless, prior to the
consummation thereof, the successor corporation (if other than the
Company) resulting from such consolidation or merger or the
corporation purchasing such assets shall assume by written
instrument reasonably satisfactory in form and substance to the
Holder executed and mailed or delivered to the registered Holder
hereof at the last address of such Holder appearing on the books of
the Company, the obligation to deliver to such Holder such shares
of stock, securities or assets as, in accordance with the foregoing
provisions, such Holder may be entitled to purchase. If there is an
Organic Change, then the Company shall cause to be mailed to the
Holder at its last address as it shall appear on the books and
records of the Company, at least 10 calendar days before the
effective date of the Organic Change, a notice stating the date on
which such Organic Change is expected to become effective or close,
and the date as of which it is expected that holders of the Common
Stock of record shall be entitled to exchange their shares for
securities, cash, or other property delivered upon such Organic
Change; provided, that the failure to mail such notice or any
defect therein or in the mailing thereof shall not affect the
validity of the corporate action required to be specified in such
notice. The Holder is entitled to exercise this Warrant during the
10-day period commencing on the date of such notice to the
effective date of the event triggering such notice. In any event,
the successor corporation (if other than the Company) resulting
from such consolidation or merger or the corporation purchasing
such assets shall be deemed to assume such obligation to deliver to
such Holder such shares of stock, securities or assets even in the
absence of a written instrument assuming such obligation to the
extent such assumption occurs by operation of
law.

 

 

7

 

(b)           Certificate
as to Adjustments. Upon the
occurrence of each adjustment or readjustment pursuant to this
Section 3, the Company at its expense shall promptly compute such
adjustment or readjustment in accordance with the terms hereof and
furnish to each Holder of this Warrant a certificate setting forth
such adjustment or readjustment and showing in detail the facts
upon which such adjustment or readjustment is based. The Company
shall promptly furnish or cause to be furnished to such Holder a
like certificate setting forth: (i) such adjustments and
readjustments; and (ii) the number of shares and the amount, if
any, of other property which at the time would be received upon the
exercise of the Warrant.

 

(c)           Certain
Events. If any event occurs as
to which the other provisions of this Section 3 are not strictly
applicable but the lack of any adjustment would not fairly protect
the purchase rights of the Holder under this Warrant in accordance
with the basic intent and principles of such provisions, or if
strictly applicable would not fairly protect the purchase rights of
the Holder under this Warrant in accordance with the basic intent
and principles of such provisions, then the Company's Board of
Directors will, in good faith, make an appropriate adjustment to
protect the rights of the Holder; provided,
that no such adjustment pursuant to this Section 3(c) will increase
the Exercise Price or decrease the number of Warrant Shares as
otherwise determined pursuant to this Section
3.

 

4.            REDEMPTION
OF WARRANTS

(a)           General.
Prior to the Expiration Date, the Company shall have the option,
subject to the conditions set forth herein, to redeem all of the
Warrants then outstanding upon not less than thirty (30) days nor
more than sixty (60) days prior written notice to the Warrant
Holders at any time provided that, at the time of delivery of such
notice (i) there is an effective registration statement
covering the resale of the Warrant Shares, and (ii) the Closing Price of the
Company’s Common Stock for each of the twenty (20)
consecutive Trading Days prior to the date of the notice of
redemption is at least $12.50, as proportionately adjusted to
reflect any stock splits, stock dividends, combination of shares or
like events. It is contemplated that Aegis Capital Corp. will be
retained as solicitation agent in the event the Company elects to
redeem the Warrants and shall be paid a fee of 5% of the gross
proceeds derived from the exercise of the Warrants in such
event.

 

(b)           Notice.
Notice of redemption will be effective upon mailing in accordance
with this Section and such date may be referred to below as the
“Notice Date.” Notice of redemption shall be mailed by
first class mail, postage prepaid, by the Company not less than 30
days prior to the date fixed for redemption to the Holders of the
Warrants to be redeemed at their last addresses as they shall
appear on the registration books. Any notice mailed in the manner
herein provided shall be conclusively presumed to have been duly
given whether or not the Holder received such
notice.

 

 

8

 

(c)           Redemption
Date and Redemption Price. The
notice of redemption shall state the date set for redemption, which
date shall be not less than thirty (30) days, or more than sixty
(60) days, from the Notice Date (the “Redemption
Date”). The Company shall
not mail the notice of redemption unless all funds necessary to pay
for redemption of the Warrants to be redeemed shall have first been
set aside by the Company for the benefit of the Warrant Holders so
as to be and continue to be available therefor. The redemption
price to be paid to the Warrant Holders will be $0.0001 for each
share of Common Stock of the Company to which the Warrant Holder
would then be entitled upon exercise of the Warrant being redeemed,
as adjusted from time to time as provided herein (the
“Redemption
Price”).

 

(d)           Exercise.
Following the Notice Date, the Warrant Holders may exercise their
Warrants in accordance with Section 1 of this Warrant between the
Notice Date and 5:00 p.m. Eastern Time on the Redemption Date and
such exercise shall be timely if the form of election to purchase
duly executed and the Warrant Exercise Price for the shares of
Common Stock to be purchased are actually received by the Company
at its principal offices prior to 5:00 p.m. Eastern Time on the
Redemption Date.

 

(e)           Mailing.
If any Warrant Holder does not wish to exercise any Warrant being
redeemed, he should mail such Warrant to the Company at its
principal offices after receiving the notice of redemption. On and
after 5:00 p.m. Eastern Time on the Redemption Date,
notwithstanding that any Warrant subject to redemption shall not
have been surrendered for redemption, the obligation evidenced by
all Warrants not surrendered for redemption or effectively
exercised shall be deemed no longer outstanding, and all rights
with respect thereto shall forthwith cease and terminate, except
only the right of the holder of each Warrant subject to redemption
to receive the Redemption Price for each share of Common Stock to
which he would be entitled if he exercised the Warrant upon
receiving notice of redemption of the Warrant subject to redemption
held by him.

 

5. TRANSFERS AND EXCHANGES OF WARRANT AND WARRANT
SHARES

 

(a)           Registration
of Transfers and Exchanges.
Subject to Section 5(c), upon the Holder’s surrender of this
Warrant, with a duly executed copy of the Form of Assignment
attached as Exhibit B, to the Secretary of the Company at its principal
offices or at such other office or agency as the Company may
specify in writing to the Holder, the Company shall register the
transfer of all or any portion of this Warrant. Upon such
registration of transfer, the Company shall issue a new Warrant, in
substantially the form of this Warrant, evidencing the acquisition
rights transferred to the transferee and a new Warrant, in similar
form, evidencing the remaining acquisition rights not transferred,
to the Holder requesting the transfer.

 

(b)           Warrant
Exchangeable for Different Denominations. The Holder may exchange this Warrant for a new
Warrant or Warrants, in substantially the form of this Warrant,
evidencing in the aggregate the right to purchase the number of
Warrant Shares which may then be purchased hereunder, each of such
new Warrants to be dated the date of such exchange and to represent
the right to purchase such number of Warrant Shares as shall be
designated by the Holder. The Holder shall surrender this Warrant
with duly executed instructions regarding such re-certification of
this Warrant to the Secretary of the Company at its principal
offices or at such other office or agency as the Company may
specify in writing to the Holder.

 

 

9

 

(c)           Restrictions
on Transfers. This Warrant may
not be transferred at any time without (i) registration under the
Securities Act or (ii) an exemption from such registration and a
written opinion of legal counsel addressed to the Company that the
proposed transfer of the Warrant may be effected without
registration under the Securities Act, which opinion will be in
form and from counsel reasonably satisfactory to the
Company.

 

(d)           Permitted
Transfers and Assignments.
Notwithstanding any provision to the contrary in this Section 5,
the Holder may transfer, with or without consideration, this
Warrant or any of the Warrant Shares (or a portion thereof) to the
Holder’s Affiliates (as such term is defined under Rule 144
of the Securities Act) without obtaining the opinion from counsel
that may be required by Section 5(c)(ii), provided,
that the Holder delivers to the
Company and its counsel certification, documentation, and other
assurances reasonably required by the Company’s counsel to
enable the Company’s counsel to render an opinion to the
Company’s Transfer Agent that such transfer does not violate
applicable securities laws.

 

6. MUTILATED OR MISSING WARRANT
CERTIFICATE

 

If this Warrant is mutilated, lost, stolen or
destroyed, upon request by the Holder, the Company will, at its
expense, issue, in exchange for and upon cancellation of the
mutilated Warrant, or in substitution for the lost, stolen or
destroyed Warrant, a new Warrant, in substantially the form of this
Warrant, representing the right to acquire the equivalent number of
Warrant Shares; provided,
that, as a prerequisite to the issuance of a substitute Warrant,
the Company may require satisfactory evidence of loss, theft or
destruction as well as an indemnity from the Holder of a lost,
stolen or destroyed Warrant.

 

7. PAYMENT OF TAXES

 

The Company will pay all transfer and stock
issuance taxes attributable to the preparation, issuance and
delivery of this Warrant and the Warrant Shares (and replacement
Warrants) including, without limitation, all documentary and stamp
taxes; provided,
however,
that the Company shall not be required to pay any tax in respect of
the transfer of this Warrant, or the issuance or delivery of
certificates for Warrant Shares or other securities in respect of
the Warrant Shares to any person or entity other than to the
Holder.

 

8. FRACTIONAL WARRANT
SHARES

 

No
fractional Warrant Shares shall be issued upon exercise of this
Warrant. The Company, in lieu of issuing any fractional Warrant
Share, shall round up the number of Warrant Shares issuable to
nearest whole share.

 

9. NO
STOCK RIGHTS AND LEGEND

 

No
holder of this Warrant, as such, shall be entitled to vote or be
deemed the holder of any other securities of the Company that may
at any time be issuable on the exercise hereof, nor shall anything
contained herein be construed to confer upon the holder of this
Warrant, as such, the rights of a stockholder of the Company or the
right to vote for the election of directors or upon any matter
submitted to stockholders at any meeting thereof, or give or
withhold consent to any corporate action or to receive notice of
meetings or other actions affecting stockholders (except as
provided herein), or to receive dividends or subscription rights or
otherwise (except as provide herein).

 

 

10

 

Each
certificate for Warrant Shares initially issued upon the exercise
of this Warrant, and each certificate for Warrant Shares issued to
any subsequent transferee of any such certificate, shall be stamped
or otherwise imprinted with a legend in substantially the following
form:

 

“THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“ACT”), OR ANY STATE SECURITIES LAWS, AND NEITHER SUCH
SECURITIES NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, PLEDGED,
ASSIGNED OR OTHERWISE TRANSFERRED UNLESS (1) A REGISTRATION
STATEMENT WITH RESPECT THERETO IS EFFECTIVE UNDER THE ACT AND ANY
APPLICABLE STATE SECURITIES LAWS, OR (2) AN EXEMPTION FROM SUCH
REGISTRATION EXISTS AND THE COMPANY RECEIVES AN OPINION OF COUNSEL
TO THE HOLDER OF SUCH SECURITIES, WHICH COUNSEL AND OPINION ARE
REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH SECURITIES MAY BE
OFFERED, SOLD, PLEDGED, ASSIGNED OR TRANSFERRED IN THE MANNER
CONTEMPLATED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT UNDER THE
ACT OR APPLICABLE STATE SECURITIES LAWS.”

 

10. REGISTRATION RIGHTS

 

The
Holder shall be entitled to the piggyback registration rights
contained in the Subscription Agreement with respect to the Warrant
Shares, the provisions of which are deemed incorporated herein by
reference.  

 

11. NOTICES

 

All notices, consents, waivers, and other
communications under this Warrant must be in writing and will be
deemed given to a party when (a) delivered to the appropriate
address by hand or by nationally recognized overnight courier
service (costs prepaid); (b) sent by facsimile or e-mail with
confirmation of transmission by the transmitting equipment; (c)
received or rejected by the addressee, if sent by certified mail,
return receipt requested, if to the registered Holder hereof; or
(d) seven days after the placement of the notice into the mails
(first class postage prepaid), to the Holder at the address,
facsimile number, or e-mail address furnished by the registered
Holder to the Company in accordance with the Subscription Agreement
by and between the Company and the Holder, or if to the Company, to
it at 301 N. Harrison
St., Suite 9F #459, Princeton, NJ 08540, Attn: Frank
Pilkiewicz, CEO (or to such
other address, facsimile number, or e-mail address as the Holder or
the Company as a party may designate by notice the other
party).

 

 

11

 

12. SEVERABILITY

 

If
a court of competent jurisdiction holds any provision of this
Warrant invalid or unenforceable, the other provisions of this
Warrant will remain in full force and effect. Any provision of this
Warrant held invalid or unenforceable only in part or degree will
remain in full force and effect to the extent not held invalid or
unenforceable.

 

13. BINDING
EFFECT

 

This
Warrant shall be binding upon and inure to the sole and exclusive
benefit of the Company, its successors and assigns, the registered
Holder or Holders from time to time of this Warrant and the Warrant
Shares.

 

14. SURVIVAL OF RIGHTS AND
DUTIES

 

This
Warrant shall terminate and be of no further force and effect on
the earlier of 5:00 P.M., Eastern Time, on the Expiration Date or
the date on which this Warrant has been exercised in
full.

 

15. GOVERNING LAW

 

This
Warrant will be governed by and construed under the laws of the
State of New York without regard to conflicts of laws principles
that would require the application of any other law.

 

16. DISPUTE RESOLUTION

 

In
the case of a dispute as to the determination of the Exercise Price
or the arithmetic calculation of the Warrant Shares, the Company
shall submit the disputed determinations or arithmetic calculations
via facsimile within two Business Days of receipt of the Notice of
Exercise giving rise to such dispute, as the case may be, to the
Holder. If the Holder and the Company are unable to agree upon such
determination or calculation of the Exercise Price or the Warrant
Shares within three Business Days of such disputed determination or
arithmetic calculation being submitted to the Holder, then the
Company shall, within two Business Days, submit via facsimile (a)
the disputed determination of the Exercise Price to an independent,
reputable investment bank selected by the Company and approved by
the Holder or (b) the disputed arithmetic calculation of the
Warrant Shares to the Company’s independent, outside
accountant. The Company shall cause at its expense the investment
bank or the accountant, as the case may be, to perform the
determinations or calculations and notify the Company and the
Holder of the results no later than ten (10) Business Days from the
time it receives the disputed determinations or calculations. Such
investment bank’s or accountant’s determination or
calculation, as the case may be, shall be binding upon all parties
absent demonstrable error.

 

17. NOTICES OF RECORD DATE

 

Upon
(a) any establishment by the Company of a record date of the
holders of any class of securities for the purpose of determining
the holders thereof who are entitled to receive any dividend or
other distribution, or right or option to acquire securities of the
Company, or any other right, or (b) any capital reorganization,
reclassification, recapitalization, merger or consolidation of the
Company with or into any other corporation, any transfer of all or
substantially all the assets of the Company, or any voluntary or
involuntary dissolution, liquidation or winding up of the Company,
or the sale, in a single transaction, of a majority of the
Company’s voting stock (whether newly issued, or from
treasury, or previously issued and then outstanding, or any
combination thereof), the Company shall mail to the Holder at least
ten (10) Business Days, or such longer period as may be required by
law, prior to the record date specified therein, a notice
specifying (i) the date established as the record date for the
purpose of such dividend, distribution, option or right and a
description of such dividend, option or right, (ii) the date on
which any such reorganization, reclassification, transfer,
consolidation, merger, dissolution, liquidation or winding up, or
sale is expected to become effective and (iii) the date, if any,
fixed as to when the holders of record of Common Stock shall be
entitled to exchange their shares of Common Stock for securities or
other property deliverable upon such reorganization,
reclassification, transfer, consolation, merger, dissolution,
liquidation or winding up.

 

 

12

 

 

18. RESERVATION OF SHARES

 

The
Company shall reserve and keep available out of its authorized but
unissued shares of Common Stock for issuance upon the exercise of
this Warrant, free from pre-emptive rights, such number of shares
of Common Stock for which this Warrant shall from time to time be
exercisable. The Company will take all such reasonable action as
may be necessary to assure that such Warrant Shares may be issued
as provided herein without violation of any applicable law or
regulation. Without limiting the generality of the foregoing, the
Company covenants that it will use commercially reasonable efforts
to take all such action as may be necessary or appropriate in order
that the Company may validly and legally issue fully paid and
nonassessable Warrant Shares upon the exercise of this Warrant and
use commercially reasonable efforts to obtain all such
authorizations, exemptions or consents, including but not limited
to consents from the Company’s stockholders or Board of
Directors or any public regulatory body, as may be necessary to
enable the Company to perform its obligations under this
Warrant.

 

19. NO
THIRD PARTY RIGHTS

 

This
Warrant is not intended, and will not be construed, to create any
rights in any parties other than the Company and the Holder, and no
person or entity may assert any rights as third-party beneficiary
hereunder.

 

 

[SIGNATURE PAGE FOLLOWS]

 

13

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be duly
executed as of the date first set forth above.

 

 

ADGERO
BIOPHARMACEUTICALS HOLDINGS, INC.

 

 

By:
___________________________

  Name: Frank Pilkiewicz

  Title: Chief Executive Officer

 

 

14

 

EXHIBIT A

 

NOTICE OF EXERCISE

 

(To be executed by the Holder of Warrant if such Holder desires to
exercise Warrant)

 

To Adgero Biopharmaceuticals Holdings, Inc.:

 

The undersigned hereby irrevocably elects to
exercise this Warrant and to purchase thereunder,
___________________ full shares of Adgero Biopharmaceuticals
Holdings, Inc. common stock issuable upon exercise of the Warrant
and delivery of:

 

(1)                 $_________
(in cash as provided for in the foregoing Warrant) and any
applicable taxes payable by the undersigned pursuant to such
Warrant; and

 

(2)                 __________
shares of Common Stock (pursuant to a Cashless Exercise in
accordance with Section 1(b)(ii) of the Warrant) (check here if the
undersigned desires to deliver an unspecified number of shares
equal the number sufficient to effect a Cashless Exercise
[___]).

 

The
undersigned requests that certificates for such shares be issued in
the name of:

 

_________________________________________

(Please print name, address and social security or federal
employer

identification number (if applicable))

 

_________________________________________

 

_________________________________________

 

The undersigned hereby reaffirms all of the
representations and warranties made in the subscription agreement
submitted to Adgero Biopharmaceuticals Holdings, Inc. to acquire the Warrant, including
that the undersigned is an accredited investor as defined under
Rule 501 of Regulation D of the Securities Act of
1933.

 

If
the shares issuable upon this exercise of the Warrant are not all
of the Warrant Shares which the Holder is entitled to acquire upon
the exercise of the Warrant, the undersigned requests that a new
Warrant evidencing the rights not so exercised be issued in the
name of and delivered to:

 

_________________________________________

(Please print name, address and social security or federal
employer

identification number (if applicable))

 

_________________________________________

 

_________________________________________

 

Name
of Holder (print): ________________________

(Signature):
___________________________________

(By:)
_________________________________________

(Title:)
________________________________________

Dated:
________________________________________

15

 

 

EXHIBIT B

 

FORM OF ASSIGNMENT

 

FOR
VALUE RECEIVED, ___________________________________ hereby sells,
assigns and transfers to each assignee set forth below all of the
rights of the undersigned under the Warrant (as defined in and
evidenced by the attached Warrant) to acquire the number of Warrant
Shares set opposite the name of such assignee below and in and to
the foregoing Warrant with respect to said acquisition rights and
the shares issuable upon exercise of the Warrant:

 

 

	

Name of Assignee

	

Address

	

Number of Shares

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

 

 

If
the total of the Warrant Shares are not all of the Warrant Shares
evidenced by the foregoing Warrant, the undersigned requests that a
new Warrant evidencing the right to acquire the Warrant Shares not
so assigned be issued in the name of and delivered to the
undersigned.

 

 

Name
of Holder (print): ________________________

(Signature):
___________________________________

(By:)
_________________________________________

(Title:)
________________________________________

Dated:
________________________________________

 

 

 

16

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00266-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00266-of-00352.parquet"}]]